Pasar al contenido principal

REPERCUSION BIOLOGICA DE LA INHIBICION DEL TRAFICO ENDOLISOSOMAL DE LIPIDOS POR AMINAS ANFIPATICAS: MECANISMOS Y PREVENCION POR POLIFENOLES

RTI2018-098113-B-I00

•
Nombre agencia financiadora Agencia Estatal de Investigación
Acrónimo agencia financiadora AEI
Programa Programa Estatal de I+D+i Orientado a los Retos de la Sociedad
Convocatoria Proyectos I+D+i Retos de Investigación
Año convocatoria 2018
Plan Estatal 2017-2020 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario FUNDACION PARA LA INVESTIGACION BIOMEDICA DEL HOSPITAL UNIVERSITARIO RAMON Y CAJAL

Resultados relacionados

Resultados totales (Incluyendo duplicados): 11
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

PCSK9 Antibodies Treatment Specifically Enhances the Macrophage-specific Reverse Cholesterol Transport Pathway in Heterozygous Familial Hypercholesterolemia

  • Borràs, Carla|||0000-0002-0998-7855
  • Canyelles, Marina|||0000-0002-0278-5337
  • Girona, Josefa
  • Ibarretxe, Daiana
  • Santos, David|||0000-0003-1157-4969
  • Revilla, Giovanna|||0000-0003-2971-5651
  • Llorente-Cortés, Vicenta|||0000-0002-0067-7201
  • Rotllan, Noemi|||0000-0002-0587-8045
  • Kovanen, Petri T.
  • Jauhiainen, Matti|||0000-0002-3836-3785
  • Lee-Rueckert, Miriam
  • Masana, Luis|||0000-0002-0789-4954
  • Arrieta, Francisco|||0000-0001-7571-0451
  • Martínez-Botas, Javier|||0000-0002-5190-3619
  • Gómez-Coronado, Diego|||0000-0002-8382-3920
  • Ribalta, Josep|||0000-0002-8879-4719
  • Tondo Colomer, Mireia|||0000-0002-0301-9984
  • Blanco Vaca, Francisco|||0000-0001-7380-5385
  • Escolà-Gil, Joan Carles|||0000-0001-9021-2485
We investigated the potential of proprotein convertase subtilisin/kexin type 9 (PCSK9) antibodies torestore macrophage cholesterol efflux in subjects with heterozygous familial hypercholesterolemia (FH)and to enhance the macrophage-specific reverse cholesterol transport pathway in mice. Analyses ofmacrophage-derived cholesterol distribution of plasma from FH patients revealed that low-density li-poprotein (LDL) particles contained less, and high-density lipoprotein particles contained more radio-labeled cholesterol after treatment with either PCSK9 inhibitor. PCSK9 antibodies facilitated thetransfer of macrophage-derived cholesterol and LDL-derived cholesterol to feces exclusively inheterozygous LDL receptor-deficient mice expressing human APOB100. PCSK9 inhibitors act aspositive regulators of the macrophage-specific reverse cholesterol transport pathway in individuals withheterozygous FH.
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

Effect of a multifactorial weight loss intervention on HDL cholesterol efflux capacity and immunosenescence: a randomized controlled trial

  • Díez-Ricote, Laura
  • Cuadrado-Soto, Esther
  • Pastor-Fernández, Andrés
  • Peña, Gema de la
  • Martinez-Botas, Javier
  • Castañer, Olga
  • Martínez-González, Miguel Ángel, 1957-
  • Salas Salvadó, Jordi
  • Fernandez-Marcos, Pablo J.
  • Gómez-Coronado, Diego
  • Ordovás, José M.
  • Daimiel, Lidia
Objective: Life expectancy and obesity prevalence are increasing worldwide, leading to an increase in the prevalence of cardiovascular disease. High-density lipoprotein (HDL) functionality and immunosenescence play key roles in cardiovascular disease, longevity, and quality of aging. Both molecular hallmarks of aging are impacted by obesity and metabolic syndrome and can be modulated by lifestyle. We aimed to evaluate the effect of a lifestyle intervention focused on an energy-reduced Mediterranean diet (erMedDiet), physical activity (PA), and behavioral support on HDL cholesterol efflux capacity (CEC) and immunosenescence. Method: CEC and immunosenescent T cells were determined in 60 participants from the control group (CG) and 56 from the intervention group (IG) of the PREDIMED-Plus trial at baseline and after 1 and 3 years of follow-up. PREDIMED-Plus is a randomized, controlled, parallel-group trial with an IG of erMedDiet, PA promotion, and behavioral support for weight loss and a CG of usual primary care advice. The sample included 116 volunteers from the PREDIMED-Plus-IMDEA subsample of the PREDIMED-Plus trial. Men aged 55 to 75 years and women aged 60 to 75 years with a body mass index between 27 and 40 kg/m2 and metabolic syndrome were included. Results: Participants within the IG had significantly improved CEC (2.42% and 10.69% after 1 and 3 years of follow-up) and a decreased in senescent T cell profile (-3.32% ± 12.54% and -6.74% ± 11.2%, p < 0.001, after 1 and 3 years of follow-up). Baseline obesity status impacted the response to the intervention. Conclusions: A weight loss intervention program with erMedDiet and PA ameliorated senescence markers., The PREDIMED-Plus-IMDEA trial was supported by CIBER Fisiopatología de la Obesidad y Nutrición (CIBEROBN) and Instituto de Salud Carlos III (ISCIII) through the Fondo de Investigación para la Salud (FIS), which is co-funded by the European Regional Development Fund (coordinated FIS projects led by JSS and JV, including the following projects: PI14/0137 and PI17/00508). ECS acknowledges financial support from the Juan de la Cierva Program Training Grants of the Spanish State Research Agency of the Spanish Ministerio de Ciencia e Innovación y Ministerio de Universidades, FJC2020-045377-I, funded by MCIN/AEI/10.13039/501100011033 and by European Union NextGenerationEU/PRTR. APF has been funded by the Spanish Association Against Cancer-AECC (PRDMA18011PAST). PJFM has been funded by a Ramon y Cajal Award from the Spanish Ministry of Science, Innovation and Universities (MICINN) (RYC-2017-22335). This study has been carried out thanks to the funds provided by Ministerio de Ciencia e Investigación through grants from PROYECTOS DE I + D + I «RETOS INVESTIGACIÓN» (RTI2018-095569-B-I00 and RTI2018-098113-B-I00) and «PROGRAMACIÓN CONJUNTA INTERNACIONAL» (PCI2018-093009). JSS was partially supported by ICREA under the ICREA Academia program.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

High-fat diet activates splenic NOD1 and enhances neutrophil recruitment and neutrophil extracellular traps release in the spleen of ApoE-deficient mice

  • Fernández-García, Victoria
  • González-Ramos, Silvia
  • Avendaño-Ortiz, José
  • Martín-Sanz, Paloma
  • Gómez-Coronado, Diego
  • Delgado, Carmen
  • Castrillo, Antonio
  • Boscá, Lisardo
In the course of atherogenesis, the spleen plays an important role in the regulation of extramedullary hematopoiesis, and in the control of circulating immune cells, which contributes to plaque progression. Here, we have investigated the role of splenic nucleotide-binding oligomerization domain 1 (NOD1) in the recruitment of circulating immune cells, as well as the involvement of this immune organ in extramedullary hematopoiesis in mice fed on a high-fat high-cholesterol diet (HFD). Under HFD conditions, the absence of NOD1 enhances the mobilization of immune cells, mainly neutrophils, from the bone marrow to the blood. To determine the effect of NOD1-dependent mobilization of immune cells under pro-atherogenic conditions, Apoe−/− and Apoe−/−Nod1−/− mice fed on HFD for 4 weeks were used. Splenic NOD1 from Apoe−/− mice was activated after feeding HFD as inferred by the phosphorylation of the NOD1 downstream targets RIPK2 and TAK1. Moreover, this activation was accompanied by the release of neutrophil extracellular traps (NETs), as determined by the increase in the expression of peptidyl arginine deiminase 4, and the identification of citrullinated histone H3 in this organ. This formation of NETs was significantly reduced in Apoe−/−Nod1−/− mice. Indeed, the presence of Ly6G+ cells and the lipidic content in the spleen of mice deficient in Apoe and Nod1 was reduced when compared to the Apoe−/− counterparts, which suggests that the mobilization and activation of circulating immune cells are altered in the absence of NOD1. Furthermore, confirming previous studies, Apoe−/−Nod1−/− mice showed a reduced atherogenic disease, and diminished recruitment of neutrophils in the spleen, compared to Apoe−/− mice. However, splenic artery ligation reduced the atherogenic burden in Apoe−/− mice an effect that, unexpectedly was lost in Apoe−/−Nod1−/− mice. Together, these results suggest that neutrophil accumulation and activity in the spleen are driven in part by NOD1 activation in mice fed on HFD, contributing in this way to regulating atherogenic progression., This work has been supported by: Ministerio de Ciencia, Investigación y Universidades, Agencia Estatal de Investigación *** (PID2019-104284RB-I00, PID2020-113238RB-I00, RTI2018-098113B-I00, PID2019-108977RB-I00), Centro de Investigación Biomédica en Red en Enfermedades Cardiovasculares (CB16/11/00222) and Consorcio de Investigación en Red de la Comunidad de Madrid, S2017/BMD-3686, Fondo Social Europeo and Fondo Europeo de Desarrollo Regional.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

MiR-7 controls cholesterol biosynthesis through posttranscriptional regulation of DHCR24 expression

  • Fernández-de Frutos, Mario
  • Pardo-Marqués, Virginia
  • Torrecilla-Parra, Marta
  • Rada, Patricia
  • Pérez-García, Ana
  • Martín-Martín, Yolanda
  • Peña, Gema de la
  • Gómez Peris, Ana
  • Toledano-Zaragoza, Ana
  • Gómez-Coronado, Diego
  • Casarejos, María José
  • Solís, José M.
  • Rotllan, Noemí
  • Pastor, Óscar
  • Ledesma, M. Dolores
  • Valverde, Ángela M.
  • Busto, Rebeca
  • Ramírez, Cristina M.
Dysregulation of cholesterol homeostasis is associated with several pathologies including cardiovascular diseases and neurological disorders such as Alzheimer's disease (AD). MicroRNAs (miRNAs) have emerged as key post-transcriptional regulators of cholesterol metabolism. We previously established the role of miR-7 in regulating insulin resistance and amyloidosis, which represents a common pathological feature between type 2 diabetes and AD. We show here an additional metabolic function of miR-7 in cholesterol biosynthesis. We found that miR-7 blocks the last steps of the cholesterol biosynthetic pathway in vitro by targeting relevant genes including DHCR24 and SC5D posttranscriptionally. Intracranial infusion of miR-7 on an adeno-associated viral vector reduced the expression of DHCR24 in the brain of wild-type mice, supporting in vivo miR-7 targeting. We also found that cholesterol regulates endogenous levels of miR-7 in vitro, correlating with transcriptional regulation through SREBP2 binding to its promoter region. In parallel to SREBP2 inhibition, the levels of miR-7 and hnRNPK (the host gene of miR-7) were concomitantly reduced in brain in a mouse model of Niemann Pick type C1 disease and in murine fatty liver, which are both characterized by intracellular cholesterol accumulation. Taken together, the results establish a novel regulatory feedback loop by which miR-7 modulates cholesterol homeostasis at the posttranscriptional level, an effect that could be exploited for therapeutic interventions against prevalent human diseases., This work was supported by the “Talento Program” from the Madrid Government, Spain (2017-T1/BMD-5333 and 2021-5A/BMD-20964), (RTI2018-095061-B-I00) and (PID2021-128264OB-I00) funded by MCIN/AEI/10.13039/501100011033 and “ERDF A way of making Europe” by the European Union (to CMR); Consejería de Educación e Investigación from the Madrid Government, Spain: “Convocatoria de ayudas para la contratación de ayudantes de investigación” (PEJ-2018-AI/BMD-9724) (to CMR and MT-P); “Convocatoria de ayudas para la contratación de investigadores postdoctorales” (PEDJ-2018-POST/BDM-8900) (to CMR and AP-G) and “Convocatoria de ayudas para la contratación de investigadores predoctorales” (PEJD-2019-PRE/BMD-14499) (to CMR and YM-M) from the Madrid Government, Spain; (RTI2018-098113-B-I00) (to RB and DGC) and (PID2021-122766OB-I00) (to AMV) and (PID2020-112830RB-I00) (to MD-L) funded by MCIN/AEI/10.13039/501100011033 and “ERDF A way of making Europe” by the European Union; (PI18/01152 and PI21/01173) funded by Instituto de Salud Carlos III, (ISCIII) (to OP); Centro de Investigación Biomédica en Red de Diabetes y Enfermedades Metabólicas Asociadas (CIBERdem), Instituto de Salud Carlos III, Madrid, Spain (research contract of P-R) and 2021-5A/BMD-20964 (research contract of VP-M). We thank the Quantification and Molecular Characterization Unit and the Lipid and Lipoprotein Unit (IRYCIS) for support., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Ellagic acid and its metabolites urolithins A/B ameliorate most common disease phenotypes in cellular and mouse models for lysosomal storage disorders by enhancing extracellular vesicle secretion

  • Soto-Huelin, Beatriz
  • Babiy, Bohdan
  • Pastor, Oscar
  • Díaz-García, Mario
  • Toledano-Zaragoza, Ana
  • Frutos-Lisón, M.D.
  • Espín de Gea, Juan Carlos
  • Tomás Barberán, Francisco
  • Busto, Rebeca
  • Ledesma, M. Dolores
Niemann Pick diseases types A (NPDA) and C (NPDC) are lysosomal storage disorders (LSDs) leading to cognitive impairment, neurodegeneration, and early death. NPDA and NPDC have different genetic origins, being caused by mutations in the acid sphingomyelinase (ASM) or the cholesterol transport protein NPC1, respectively. However, they share a common pathological hallmark in the accumulation of lipids in the endolysosomal compartment. Here, we tested the hypothesis that polyphenols reduce lipid overload in NPD cells by enhancing the secretion of extracellular vesicles (ECVs). We show that among the polyphenols tested, the ellagic acid metabolites, urolithin A and B, were the safest and most efficient in increasing ECV secretion. They reduced levels of accumulating lipids and lysosomal size and permeabilization in cultured bone marrow-derived macrophages and neurons from ASMko and NPC1 mutant mice, which mimic NPDA and NPDC, respectively. Moreover, oral treatment with ellagic acid reduced lipid levels, ameliorated lysosomal alterations, and diminished microglia activation in the brain of NPD mice. These results support the therapeutic value of ECV secretion and polyphenols for NPDs, which may also help treat other LSDs characterized by intracellular lipid overload., This work was funded by grants from the Spanish Ministry of Science and Innovation (PID2020-112830RB-I00) (AEI/FEDER,UE) and the Next Generation EU-CSIC funds (NeuroAging) to M.D.L.; RTI2018-098113-B-I00 (MCIN/AEI/10.13039/501100011033) to R.B.; PI21/01173 (Instituto de Salud Carlos III, ISCIII) to O.P.; all the grants cofinanced by the European Development Regional Fund (ERDF) “A way of making Europe”. B. S–H holds a predoctoral contract (FPU) funded by the Ministerio Espanol ˜ de Ciencia e Innovacion. ´ R. B. is a researcher of the Fundación para la Investigación Biomédica del Hospital Universitario Ramón y Cajal, supported by Consejería de Sanidad (CAM)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

PCSK9 Antibodies Treatment Specifically Enhances the Macrophage-specific Reverse Cholesterol Transport Pathway in Heterozygous Familial Hypercholesterolemia

  • Borràs, Carla
  • Canyelles, Marina
  • Girona, Josefa
  • Ibarretxe, Daiana
  • Santos, David
  • Revilla, Giovanna
  • Llorente-Cortés, Vicenta
  • Rotllan, Noemí
  • Kovanen, Petri T.
  • Jauhiainen, Matti
  • Lee-Rueckert, Miriam
  • Masana, Luis
  • Arrieta, Francisco
  • Martínez-Botas, Javier
  • Gómez-Coronado, Diego
  • Ribalta, Josep
  • Tondo, Mireia
  • Blanco-Vaca, Francisco
  • Escolà-Gil, Joan Carles
We investigated the potential of proprotein convertase subtilisin/kexin type 9 (PCSK9) antibodies to restore macrophage cholesterol efflux in subjects with heterozygous familial hypercholesterolemia (FH) and to enhance the macrophage-specific reverse cholesterol transport pathway in mice. Analyses of macrophage-derived cholesterol distribution of plasma from FH patients revealed that low-density lipoprotein (LDL) particles contained less, and high-density lipoprotein particles contained more radiolabeled cholesterol after treatment with either PCSK9 inhibitor. PCSK9 antibodies facilitated the transfer of macrophage-derived cholesterol and LDL-derived cholesterol to feces exclusively in heterozygous LDL receptor-deficient mice expressing human APOB100. PCSK9 inhibitors act as positive regulators of the macrophage-specific reverse cholesterol transport pathway in individuals with heterozygous FH., This work was partly funded by the Instituto de Salud Carlos III and FEDER “Una manera de hacer Europa” grants PI2100140 (to Dr Blanco-Vaca and Dr Tondo), PI2101523 (to Dr Llorente-Cortes), PI2300232 (to Dr Canyelles and Dr Escolà-Gil), JR22/00003 (to Dr Canyelles), by the Ministerio de Ciencia e Innovación grant RTI2018-098113-B-I00 (to Dr Gómez-Coronado), by BBVA Foundation Ayudas a Equipos de Investigación 2019 to the project “Translational Molecular Imaging for detection of Cholesterol Entrapment in the Vasculature with 68Ga-labeled LRP1-derived peptides” (to Dr Llorente-Cortes) and grant 12/C/2015 from La Fundació la Marató TV3 (to Dr Masana and Dr Blanco-Vaca); the Jane and Aatos Erkko Foundation (to Dr Jauhiainen), and the Finnish Foundation for Cardiovascular Research (to Dr Jauhiainen). Ms Borràs was funded with a Formación de Profesorado Universitario grant FPU20/07440 from the Ministerio de Universidades. Dr Rotllan was funded by Agencia Estatal de Investigación (AEI/10.13039/501100011033) within the Subprograma Ramón y Cajal (RYC-201722879). CIBERDEM and CIBERCV are Instituto de Salud Carlos III projects. All authors have reported that they have no relationships relevant to the contents of this paper to disclose., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Milk and cheesemaking whey as a sustainable source of extracellular vesicles: Exploring large-scale isolation methods with industrial and potential therapeutic applications

  • Del Saz-Lara, Andrea
  • López de Las Hazas, María-Carmen
  • Tomé-Carneiro, João
  • Mazarío-Gárgoles, Carmen
  • Gil-Zamorano, Judit
  • Balaguer, Livia
  • Del Pozo-Acebo, Lorena
  • González-Sarrías, Antonio
  • Ávila-Gálvez, María Ángeles
  • Espín de Gea, Juan Carlos
  • Gómez-Coronado, Diego
  • Visioli, Francesco
  • Dávalos, Alberto
Milk extracellular vesicles (EVs) represent promising drug delivery platforms, yet current isolation methods face scalability challenges. Ultracentrifugation (UC), the gold standard, is expensive and energy-intensive, limiting pharmaceutical and pharmacological implementation. This study aimed to standardize scalable EV isolation methods and evaluate cheesemaking whey as a sustainable alternative to milk for therapeutic applications. We systematically compared isolation techniques including UC, tangential flow filtration (TFF), and polyethylene glycol (PEG) co-precipitation across milk and whey from bovine, caprine, and ovine sources. Casein removal strategies using acidification and EDTA treatment were evaluated. Functional validation included in vitro simulated gastrointestinal digestion and in vivo pharmacokinetic studies of miRNA-loaded EVs in murine models. Our results demonstrate that cheesemaking whey serves as a sustainable EV source with reduced casein contamination and comparable yields to milk. Both TFF and PEG co-precipitation effectively concentrate EVs from whey, offering viable UC alternatives for pharmaceutical scale-up, though additional purification steps are required for optimal purity. Acidification effectively removes protein contaminants from milk but shows minimal benefits for whey. Cow whey provided the highest EV yields among species evaluated. Functionally, EV-encapsulated miRNAs demonstrated superior gastrointestinal stability compared to free miRNAs and exhibited enhanced bioavailability in multiple target tissues including cardiac, splenic, and skeletal muscle following oral administration. These findings establish cheesemaking whey as a sustainable, pharmaceutical-grade EV source and validate scalable isolation methods suitable for therapeutic applications, providing essential groundwork for clinical translation of milk-derived EV-based drug delivery systems., This research was funded by MCIN/ AEI /10.13039/501100011033 through the European Union NexGenerationEU/PRTR (TED2021–130962B-C21 and TED2021–130962B-C22) and ERDF A way of making Europe (PID2022–143100OB-I00 and RTI2018–098113-B-I00), by Comunidad de Madrid EXOHEP2-CM (S2022/BMD-7409), and by the AGROALNEXT programme, supported by MCIN with funding from European Union NextGenerationEU (PRTR-C17.I1). MCLH is a recipient of a Ramon y Cajal Grant RYC2022–037626-I. CM-G is supported by a contract derived from European Union NexGenerationEU/PRTR (TED2021–130962B-C21). FV is partially supported by PRIN-2022 Prot. 2022NZNZH8. CIBEROBN (CB22/03/00068) is an initiative of the Instituto de Salud Carlos III, Spain, Peer reviewed
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Effect of a multifactorial weight loss intervention on HDL cholesterol efflux capacity and immunosenescence: a randomized controlled trial

  • Díez-Ricote, Laura
  • Cuadrado-Soto, Esther
  • Pastor-Fernández, Andrés
  • Peña, Gema de la
  • Martinez-Botas, Javier
  • Castañer, Olga
  • Martínez-González, Miguel Ángel, 1957-
  • Salas Salvadó, Jordi
  • Fernandez-Marcos, Pablo J.
  • Gómez-Coronado, Diego
  • Ordovás, José M.
  • Daimiel, Lidia
Objective: Life expectancy and obesity prevalence are increasing worldwide, leading to an increase in the prevalence of cardiovascular disease. High-density lipoprotein (HDL) functionality and immunosenescence play key roles in cardiovascular disease, longevity, and quality of aging. Both molecular hallmarks of aging are impacted by obesity and metabolic syndrome and can be modulated by lifestyle. We aimed to evaluate the effect of a lifestyle intervention focused on an energy-reduced Mediterranean diet (erMedDiet), physical activity (PA), and behavioral support on HDL cholesterol efflux capacity (CEC) and immunosenescence. Method: CEC and immunosenescent T cells were determined in 60 participants from the control group (CG) and 56 from the intervention group (IG) of the PREDIMED-Plus trial at baseline and after 1 and 3 years of follow-up. PREDIMED-Plus is a randomized, controlled, parallel-group trial with an IG of erMedDiet, PA promotion, and behavioral support for weight loss and a CG of usual primary care advice. The sample included 116 volunteers from the PREDIMED-Plus-IMDEA subsample of the PREDIMED-Plus trial. Men aged 55 to 75 years and women aged 60 to 75 years with a body mass index between 27 and 40 kg/m2 and metabolic syndrome were included. Results: Participants within the IG had significantly improved CEC (2.42% and 10.69% after 1 and 3 years of follow-up) and a decreased in senescent T cell profile (-3.32% ± 12.54% and -6.74% ± 11.2%, p < 0.001, after 1 and 3 years of follow-up). Baseline obesity status impacted the response to the intervention. Conclusions: A weight loss intervention program with erMedDiet and PA ameliorated senescence markers., The PREDIMED-Plus-IMDEA trial was supported by CIBER Fisiopatología de la Obesidad y Nutrición (CIBEROBN) and Instituto de Salud Carlos III (ISCIII) through the Fondo de Investigación para la Salud (FIS), which is co-funded by the European Regional Development Fund (coordinated FIS projects led by JSS and JV, including the following projects: PI14/0137 and PI17/00508). ECS acknowledges financial support from the Juan de la Cierva Program Training Grants of the Spanish State Research Agency of the Spanish Ministerio de Ciencia e Innovación y Ministerio de Universidades, FJC2020-045377-I, funded by MCIN/AEI/10.13039/501100011033 and by European Union NextGenerationEU/PRTR. APF has been funded by the Spanish Association Against Cancer-AECC (PRDMA18011PAST). PJFM has been funded by a Ramon y Cajal Award from the Spanish Ministry of Science, Innovation and Universities (MICINN) (RYC-2017-22335). This study has been carried out thanks to the funds provided by Ministerio de Ciencia e Investigación through grants from PROYECTOS DE I + D + I «RETOS INVESTIGACIÓN» (RTI2018-095569-B-I00 and RTI2018-098113-B-I00) and «PROGRAMACIÓN CONJUNTA INTERNACIONAL» (PCI2018-093009). JSS was partially supported by ICREA under the ICREA Academia program.
Docta Complutense
Publicación Artículo científico (JournalArticle)

MiR-7 inhibits progression of glioblastoma by impairing autophagy resolution, energy metabolism and ECM remodeling

  • Torrecilla Parra, Marta
  • Pardo Marqués, Virginia
  • Fuentes Fayos, Antonio C.
  • G. García, Miguel E.
  • Fernández de Frutos, Mario
  • López Aceituno, José L.
  • Puigdueta, Cristina
  • Zamora, Carmen
  • Pérez García, Ana
  • Aranda Gómez, Juan Francisco
  • Busto, Rebeca
  • Gahete, Manuel D.
  • Luque, Raúl M.
  • Ramírez, Cristina M.
Background. Due to the poor prognosis of patients suffering malignant brain tumors such as glioblastoma multiforme (GBM), the search for new therapeutic strategies with more efficacy and higher survival rate is of utmost urgency. Growing evidence suggests that alterations in autophagy and metabolism critically contribute to the pathogenesis and progression of GBM. In this context, microRNAs are known to regulate autophagy and associated cellular functions, which point them as promising therapeutic candidates. We previously established the role of miR-7 in regulating relevant metabolic pathways related to insulin signaling and cholesterol homeostasis. Methods, Bioinformatics analysis was performed to identify miR-7 target genes potentially involved in the regulation of metabolism and cellular processes related to GBM. Ectopic expression of miR-7 was assessed to investigate its role in macroautophagy and energy metabolism. In vivo, miR-7 levels were restored in a mouse GBM xenograft model to evaluate its potential therapeutic effect in already established tumors. Additional mechanistic approaches, including transcriptomics, bioinformatics, and histopathological analyses, indicate that miR-7 modifies the tumor phenotype by altering key genes involved in extracellular matrix (ECM) remodeling in vivo. Results. Herein, we unveiled new conceptual and functional pathophysiological avenues in GBM, with potential therapeutic implications, by demonstrating a novel dual role of miR-7 on the regulation of metabolism, through the impairment of the mitochondrial function and glycolysis, and autophagy, by inducing the initiation process through the regulation of PI3K/AKT/mTORC1 signaling, while blocking later stages via posttranscriptional inhibition of two key SNARE proteins, STX17 and SNAP29. Furthermore, in vivo studies using a preclinical model showed that miR-7 overexpression in already established GBM tumors promotes a significant inhibition of tumor size and progression and replicates the metabolic defects found in vitro. Moreover, our novel findings indicate that miR-7 modifies the tumor phenotype by promoting alterations in its mechanism of extracellular matrix remodeling in vivo. Conclusion. Altogether, our study provides solid, convincing evidence demonstrating that miR-7 might be used as a promising therapeutic target for GBM, paving the way to explore its potential as novel biomarker and actionable target candidate for this lethal cancer.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Selective estrogen receptor modulators (SERMs) affect cholesterol homeostasis through the master regulators SREBP and LXR

  • Fernández-Suárez, María E.|||0000-0003-4277-2079
  • Daimiel, Lidia|||0000-0001-9898-6629
  • Villa-Turégano, Gemma
  • Vázquez Pavón, María
  • Busto, Rebeca
  • Escolà-Gil, Joan Carles|||0000-0001-9021-2485
  • Platt, Frances M.
  • Lasunción, Miguel A.|||0000-0003-0299-9391
  • Martínez-Botas, Javier|||0000-0002-5190-3619
  • Gómez-Coronado, Diego|||0000-0002-8382-3920
Selective estrogen receptor modulators (SERMs) are nonsteroidal drugs that display an estrogen-agonist or estrogen-antagonist effect depending on the tissue targeted. SERMs have attracted great clinical interest for the treatment of several pathologies, most notably breast cancer and osteoporosis. There is strong evidence that SERMs secondarily affect cholesterol metabolism, although the mechanism has not been fully elucidated. In this study, we analysed the effect of the SERMs tamoxifen, raloxifene, and toremifene on the expression of lipid metabolism genes by microarrays and quantitative PCR in different cell types, and ascertained the main mechanisms involved. The three SERMs increased the expression of sterol regulatory element-binding protein (SREBP) target genes, especially those targeted by SREBP-2. In consonance, SERMs increased SREBP-2 processing. These effects were associated to the interference with intracellular LDL-derived cholesterol trafficking. When the cells were exposed to LDL, but not to cholesterol/methyl-cyclodextrin complexes, the SERM-induced increases in gene expression were synergistic with those induced by lovastatin. Furthermore, the SERMs reduced the stimulation of the transcriptional activity of the liver X receptor (LXR) by exogenous cholesterol. However, their impact on the expression of the LXR canonical target ABCA1 in the presence of LDL was cell-type dependent. These actions of SERMs were independent of estrogen receptors. We conclude that, by inhibiting the intracellular trafficking of LDL-derived cholesterol, SERMs promote the activation of SREBP-2 and prevent the activation of LXR, two master regulators of cellular cholesterol metabolism. This study highlights the impact of SERMs on lipid homeostasis regulation beyond their actions as estrogen receptor modulators.
e_Buah Biblioteca Digital Universidad de Alcalá
Publicación Artículo científico (JournalArticle)

Role of miR-199a-5p in the post-transcriptional regulation of ABCA1 in response to hypoxia in peritoneal macrophages

  • Aranda Gómez, Juan Francisco
  • Pérez García, Ana
  • Torrecilla Parra, Marta
  • Fernández de Frutos, Mario
  • Martín Martín, Yolanda
  • Mateos Gómez, Pedro Antonio|||0000-0002-5539-2289
  • Pardo Marqués, Virginia
  • Busto Durán, Rebeca
  • Ramírez, Cristina M.
15 p., Hypoxia is a crucial factor contributing to maintenance of atherosclerotic lesions. The ability of ABCA1 to stimulate the efflux of cholesterol from cells in the periphery, particularly foam cells in atherosclerotic plaques, is an important anti-atherosclerotic mechanism. The posttranscriptional regulation by miRNAs represents a key regulatory mechanism of a number of signaling pathways involved in atherosclerosis. Previously, miR-199a-5p has been shown to be implicated in the endocytic and retrograde intracellular transport. Although the regulation of miR-199a-5p and ABCA1 by hypoxia has been already reported independently, the role of miR-199a-5p in macrophages and its possible role in atherogenic processes such us regulation of lipid homeostasis through ABCA1 has not been yet investigated. Here, we demonstrate that both ABCA1 and miR-199a-5p show an inverse regulation by hypoxia and Ac-LDL in primary macrophages. Moreover, we demonstrated that miR-199a-5p regulates ABCA1 mRNA and protein levels by directly binding to its 3?UTR. As a result, manipulation of cellular miR-199a-5p levels alters ABCA1 expression and cholesterol efflux in primary mouse macrophages. Taken together, these results indicate that the correlation between ABCA1-miR-199a-5p could be exploited to control macrophage cholesterol efflux during the onset of atherosclerosis, where cholesterol alterations and hypoxia play a pathogenic role., Comunidad de Madrid, Agencia Estatal de Investigación, Unión Europea